Determinants of undercarboxylated and carboxylated osteocalcin concentrations in type 1 diabetes
- PMID: 22068385
- PMCID: PMC3471372
- DOI: 10.1007/s00198-011-1807-7
Determinants of undercarboxylated and carboxylated osteocalcin concentrations in type 1 diabetes
Abstract
To determine whether undercarboxylated osteocalcin (UC-OC) or gamma-carboxyglutamic-carboxylated-type osteocalcin (GLA-OC) concentrations deviate from normal in type 1 diabetes (T1D), serum levels were compared between 115 subjects with T1D and 55 age-matched healthy controls. UC-OC and GLA-OC concentrations were similar between groups; however, in T1D, UC-OC correlated positively with markers of insulin exposure, either endogenously produced or exogenously administered.
Introduction: A study was conducted to determine whether dysregulation of circulating concentrations of UC-OC or GLA-OC occurs in patients with type 1 diabetes, a condition of insulin deficiency without insulin resistance.
Methods: We measured serum concentrations of UC-OC and GLA-OC in 115 subjects with T1D, ages 14-40 years, and in 55 age-matched healthy control subjects. Relationships between UC-OC and GLA-OC concentrations and patient characteristics (gender and age), indices of glycemic control (hemoglobin A1c (HbA1c), fasting plasma glucose, C-peptide concentration, 3-day average glucose measured by a continuous glucose sensor, total daily insulin dose) and circulating indices of skeletal homeostasis (total calcium, 25-OH vitamin D, parathyroid hormone, insulin-like growth factor 1 (IGF-1), type 1 collagen degradation fragments (CTX), adiponectin, leptin) were examined. Between group differences in the concentrations of UC-OC and GLA-OC were the main outcome measures.
Results: Although adiponectin levels were higher in the T1D group, between-group comparisons did not reveal statistically significant differences in concentration of UC-OC, GLA-OC, CTX or leptin between the T1D and control populations. Instead, by multivariate regression modeling, UC-OC was correlated with younger age (p < 0.001), higher CTX (p < 0.001), lower HbA1c (p = 0.013), and higher IGF-1 (p = 0.086). Moreover, within the T1D subgroup, UC-OC was positively correlated with C-peptide/glucose ratio (reflecting endogenous insulin secretion), with IGF-1 (reflecting intra-portal insulin sufficiency), and with total daily insulin dose.
Conclusions: In T1D, UC-OC appears to correlate positively with markers of insulin exposure, either endogenously produced or exogenously administered.
Conflict of interest statement
Similar articles
-
Osteocalcin, adipokines and their associations with glucose metabolism in type 1 diabetes.Bone. 2016 Jan;82:50-5. doi: 10.1016/j.bone.2015.04.017. Epub 2015 Apr 16. Bone. 2016. PMID: 25888930
-
Decreased undercarboxylated osteocalcin in children with type 2 diabetes mellitus.J Pediatr Endocrinol Metab. 2016 Aug 1;29(8):879-84. doi: 10.1515/jpem-2015-0417. J Pediatr Endocrinol Metab. 2016. PMID: 27383868
-
Carboxylated and undercarboxylated osteocalcin in metabolic complications of human obesity and prediabetes.Diabetes Metab Res Rev. 2017 Mar;33(3):e2862. doi: 10.1002/dmrr.2862. Epub 2016 Nov 7. Diabetes Metab Res Rev. 2017. PMID: 27667744 Free PMC article.
-
Molecular modulation of osteocalcin and its relevance in diabetes (Review).Int J Mol Med. 2011 Sep;28(3):283-93. doi: 10.3892/ijmm.2011.706. Epub 2011 May 23. Int J Mol Med. 2011. PMID: 21617842 Review.
-
Current knowledge of bone-derived factor osteocalcin: its role in the management and treatment of diabetes mellitus, osteoporosis, osteopetrosis and inflammatory joint diseases.J Mol Med (Berl). 2024 Apr;102(4):435-452. doi: 10.1007/s00109-024-02418-8. Epub 2024 Feb 16. J Mol Med (Berl). 2024. PMID: 38363329 Free PMC article. Review.
Cited by
-
Diabetes pharmacotherapy and effects on the musculoskeletal system.Diabetes Metab Res Rev. 2019 Feb;35(2):e3100. doi: 10.1002/dmrr.3100. Epub 2018 Dec 20. Diabetes Metab Res Rev. 2019. PMID: 30467957 Free PMC article. Review.
-
PHEX mimetic (SPR4-peptide) corrects and improves HYP and wild type mice energy-metabolism.PLoS One. 2014 May 19;9(5):e97326. doi: 10.1371/journal.pone.0097326. eCollection 2014. PLoS One. 2014. PMID: 24839967 Free PMC article.
-
Contributions of the Insulin/Insulin-Like Growth Factor-1 Axis to Diabetic Osteopathy.J Diabetes Metab. 2011 Nov 25;1(3):S1-003. doi: 10.4172/2155-6156.S1-003. J Diabetes Metab. 2011. PMID: 23484069 Free PMC article.
-
The Endocrine Role of Bone in Cardiometabolic Health.Curr Nutr Rep. 2019 Sep;8(3):281-294. doi: 10.1007/s13668-019-00286-0. Curr Nutr Rep. 2019. PMID: 31297756 Review.
-
TGFβ Regulation of Perilacunar/Canalicular Remodeling Is Sexually Dimorphic.J Bone Miner Res. 2020 Aug;35(8):1549-1561. doi: 10.1002/jbmr.4023. Epub 2020 May 13. J Bone Miner Res. 2020. PMID: 32282961 Free PMC article.
References
-
- Craig ME, Hattersley A, Donaghue K. ISPAD Clinical Practice Consensus Guidelines 2006–2007. Definition, epidemiology and classification. Pediatr Diabetes. 2006;7:343–351. - PubMed
-
- Thrailkill KM. Insulin-like growth factor-I in diabetes mellitus: its physiology, metabolic effects, and potential clinical utility. Diabetes Technol Ther. 2000;2:69–80. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
